Stephens Inc. AR Trims Position in Johnson & Johnson $JNJ

Stephens Inc. AR cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 194,814 shares of the company’s stock after selling 2,387 shares during the quarter. Stephens Inc. AR’s holdings in Johnson & Johnson were worth $36,122,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of JNJ. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson during the second quarter worth approximately $27,000. Clayton Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $28,000. Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $35,000. Finally, Signature Resources Capital Management LLC boosted its holdings in Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after acquiring an additional 184 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.3%

Shares of NYSE:JNJ opened at $218.81 on Friday. The company’s fifty day moving average is $205.82 and its two-hundred day moving average is $186.74. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $220.11. The stock has a market capitalization of $527.18 billion, a price-to-earnings ratio of 21.12, a price-to-earnings-growth ratio of 2.26 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 14th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.76 by $0.04. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $23.99 billion during the quarter, compared to the consensus estimate of $23.73 billion. During the same quarter in the prior year, the firm earned $2.42 EPS. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research report on Monday, October 20th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Sanford C. Bernstein upped their price target on Johnson & Johnson from $193.00 to $208.00 and gave the stock a “market perform” rating in a report on Friday, January 9th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Finally, Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday. Four analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.